Oncology

With new kits for complex cell models, Atrandi's semi-permeable capsules challenge market leaders by enabling multi-step workflows previously out of reach.

With two blockbuster cancer drugs driving record revenue, all eyes are on Syndax's upcoming earnings call for its 2026 outlook and growth strategy.

With a major €12.5M EU funding package, Step Pharma is fast-tracking dencatistat, a novel therapy targeting a key vulnerability in ovarian and endometrial cancers.

An international team, backed by a $2M grant from a global consortium and Microsoft, will use AI to personalize care for a long-overlooked disease.

Early data reveals a novel immunotherapy, STC-1010, may activate the immune system against a common, treatment-resistant form of colorectal cancer.

Flatiron Health launches a first-of-its-kind AI platform, merging data from 400,000 patients to revolutionize prostate cancer research and treatment.

A new cancer care company has tapped titans of medicine, policy, and patient advocacy to guide its mission of transforming treatment from the clinic to the home.

New head-to-head study results for POSLUMA PET imaging could redefine diagnostic clarity for prostate cancer, promising earlier and more precise detection.

As Jazz Pharmaceuticals preps for key investor talks, all eyes are on its blockbuster pipeline, revenue growth, and strategy to fend off competition.

With a $50.1M financing led by top investors, Coherus solidifies its strategic pivot from biosimilars to a pure-play oncology powerhouse.

Genmab posts record 2025 revenue, driven by cancer drug sales and a major acquisition, setting an ambitious, investment-heavy course for 2026.

Pioneering surgeon Dr. Gopal H. Badlani receives a top honor for his decades of work building sustainable urological care in underserved nations.

Sanofi promotes Dupixent growth driver Manuela Buxo to lead its crucial Specialty Care unit, ensuring continuity as competition and a new AI focus intensify.

Accord Healthcare's launch of generic lenalidomide signals a new era of affordability for a key cancer drug, intensifying competition and lowering costs.

A new supply agreement for the rare isotope Actinium-225 between NorthStar and BIOEMTECH promises to break a critical bottleneck in radiopharmaceutical R&D.

A new FDA approval allows a lung cancer therapy to be given just once a month, a major shift promising to reduce clinic time and improve quality of life.

After a $6M cash infusion and leadership change, the diagnostics firm is selling its flagship product to chase a high-risk, high-reward U.S. market.

Amidst a volatile stock history, GT Biopharma aims to secure vital funding for its innovative NK cell therapy pipeline at a key Toronto conference.

With a massive dataset from $6.2B in prior authorizations, SamaCare's AI is speeding up access to critical drugs, but raises questions about market power.

A genomic test identifies which breast cancer patients truly benefit from extended hormone therapy, a major step toward personalized long-term care.